The agency has clarified its expectation that manufacturers of emergency use authorization (eua) products for sars-cov-2 diagnostic tests report allegations of false positive or false negative results independent of harm or malfunction or off-label use beyond 803s "reasonably suggests" requirements.Accordingly, we have performed a retrospective review of cases to determine whether to report any additional cases.A customer from (b)(6) alleged discrepant results with the cobas¿ sars-cov-2 assay.A review of the provided data confirmed that sample id (b)(6) generated a positive result for target 1 with a ct value of 36.5 and negative for target 2 and ic ct of 33.17.No harm or injury was indicated.A review of the positive growth curves showed a very flat curve with a late rise in fluorescence corresponding with the late ct values.Additionally, the ic does not appear to be delayed.The alleged runs contained valid roche controls and are in line with release data.The sample was retested with the cobas¿ sars-cov-2, cepheid, and altona realstar assays and all were negative.The retest data on the cobas¿ sars-cov-2 was not available to be provided.Information is not available regarding whether any of the results were reported to the patient.The customer confirmed that the assay was used for screening purposes.The samples were nasopharyngeal swabs collected in a utm collection media tube.The late ct value of 36.5 for target 1 is indicative of a sample near or below the limit of detection (lod) of the assay.As per table: lod determination using usa-wa1/2020 strain in the method sheet this would correspond to a hit rate of less than 38.1%.As such, results can waiver between positive and negative as observed here with the alleged samples.According to the instructions for use, the cobas sars-cov-2 for use on the cobas 6800/8800 systems is a real-time rt-pcr test intended for the qualitative detection of nucleic acids from sars-cov-2 in clinician-instructed self-collected nasal swab specimens (collected on site), and clinician-collected nasal, nasopharyngeal, and oropharyngeal swab specimens from individuals who meet covid-19 clinical and/or epidemiological criteria.The cobas sars-cov-2 is a qualitative test for use on the cobas 6800/8800 system for the detection of the 2019 novel coronavirus(sars-cov-2) rna in nasal, nasopharyngeal, and oropharyngeal swab samples collected in copan universal transport medium system (utm-rt),bd universal viral transport system (uvt), cobas pcr media, or 0.9% physiological saline.Based on the totality of the information and data provided, the assay is working as intended.
|